Jack K

Good Riddance to 2008

Thanks for the tip Stox, on KOOL, but Small biotechs with good ideas without profits are very risky. I am a board certified immunologist and I think that the profit potential in the near term for this type of company is low. I suspect their research is sound, but it is unlikely that they could bring a drug to market, and the demand for their product strikes me as unlikely to be increasing significantly. They will burn a lot of cash and their stock price at less than 50 cents reflects this.